Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis.
CONCLUSIONS: Our review, which provided mainly data on adults, suggests on the basis of mostly low- to very low-quality evidence that there are neither advantages nor disadvantages when comparing the effects of subcutaneous rapid-acting insulin analogues versus intravenous regular insulin for treating mild or moderate DKA.
PMID: 26798030 [PubMed - as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - January 21, 2016 Category: Journals (General) Authors: Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, Gonzalez-Padilla DA Tags: Cochrane Database Syst Rev Source Type: research
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.
Abstract
Dulaglutide is a,new once-weekly glucagon-like peptide-1 receptor agonist for the management of hyperglycemia in adult patients with type 2 diabetes. It stimulates dose-dependent insulin secretion and reduces glucagon secretion, both in a glucose-dependent manner. Efficacy on blood glucose control and safety were demonstrated in the large AWARD program in type 2 diabetic patients treated with diet, metformin, dual oral therapy or insulin lispro with or without metformin, confirming findings of pilot studies in Caucasian patients and data in Japanese patients. Dulaglutide 1.5 mg once weekly was sup...
Source: Pharmacological Reviews - January 13, 2016 Category: Drugs & Pharmacology Authors: Scheen AJ Tags: Expert Rev Clin Pharmacol Source Type: research
Influence of postprandial hyperglycemic conditions on arterial stiffness in patients with type 2 diabetes.
CONCLUSIONS: In patients with T2D and albuminuria, brachial PWV was higher under postprandial hyperglycemic conditions, relative to controls. These data suggest that hyperglycemia induces an increase in stiffness of intermediate-sized arteries. We found no changes in other parts of the arterial bed.
PMID: 26731258 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - January 5, 2016 Category: Endocrinology Authors: Gordin D, Saraheimo M, Tuomikangas J, Soro-Paavonen A, Forsblom C, Paavonen K, Steckel-Hamann B, Vandenhende F, Nicolaou L, Pavo I, Koivisto V, Groop PH Tags: J Clin Endocrinol Metab Source Type: research
Comparison of Subcutaneous Regular Insulin and Lispro Insulin in Diabetics Receiving Continuous Nutrition: A Numerical Study
Conclusions:
Subcutaneous regular insulin may be the short-acting insulin preparation of choice for this subset of diabetic patients. Clinical trial is required before a definitive recommendation can be made. (Source: Journal of Diabetes Science and Technology)
Source: Journal of Diabetes Science and Technology - December 30, 2015 Category: Endocrinology Authors: Stull, M. C., Strilka, R. J., Clemens, M. S., Armen, S. B. Tags: Original Articles Source Type: research
Pharmacokinetics and pharmacodynamics of insulin glargine-insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals
Conclusions Glargine/glulisine pharmacokinetics in type 1 diabetes can closely approximate physiologic insulin responses in healthy individuals during a day in which three standardized meals are consumed. Additionally, when glulisine is dosed only five minutes pre-meal, systemic insulin concentration rises as rapidly as prandial endogenous insulin levels. This present study compared glargine and glulisine administered in an approximate 50/50 proportion. Future study of alternate meal times, meal content and differing premixed insulin preparations are indicated. (Source: Journal of Clinical and Translational Endocrinology)
Source: Journal of Clinical and Translational Endocrinology - December 25, 2015 Category: Endocrinology Source Type: research
Intranasal Insulin Improves Age-Related Cognitive Deficits and Reverses Electrophysiological Correlates of Brain Aging
Peripheral insulin resistance is a key component of metabolic syndrome associated with obesity, dyslipidemia, hypertension, and type 2 diabetes. While the impact of insulin resistance is well recognized in the periphery, it is also becoming apparent in the brain. Recent studies suggest that insulin resistance may be a factor in brain aging and Alzheimer’s disease (AD) whereby intranasal insulin therapy, which delivers insulin to the brain, improves cognition and memory in AD patients. Here, we tested a clinically relevant delivery method to determine the impact of two forms of insulin, short-acting insulin lispro (Hu...
Source: Journals of Gerontology Series A: Biological Sciences and Medical Sciences - December 16, 2015 Category: Geriatrics Authors: Maimaiti, S., Anderson, K. L., DeMoll, C., Brewer, L. D., Rauh, B. A., Gant, J. C., Blalock, E. M., Porter, N. M., Thibault, O. Tags: Original Article Source Type: research
Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes mellitus requiring insulin intensification—a randomized phase IV trial: Indian subpopulation analyses
Abstract
The aim of this study was to describe the efficacy and safety of two insulin intensification strategies in patients recruited in India with type 2 diabetes mellitus inadequately controlled on basal insulin glargine with metformin and/or pioglitazone. This multinational, open-label, randomized, parallel-arm, noninferiority, phase IV clinical trial evaluated insulin lispro low mixture (LM25) and basal insulin glargine administered with prandial insulin lispro (IGL) for 24 weeks. Patients were male and female, aged ≥18 to ≤75 years, with screening glycosylated hemoglobin (HbA1c) concentration ...
Source: International Journal of Diabetes in Developing Countries - November 2, 2015 Category: Endocrinology Source Type: research
Use of Insulin Lispro Protamine Suspension in Pregnancy
Abstract
Maternal metabolism changes substantially during pregnancy, which poses numerous challenges to physicians managing pregnancy in women with diabetes. Insulin is the agent of choice for glycemic control in pregnant women with diabetes, and the insulin analogs are particularly interesting for use in pregnancy. These agents may reduce the risk of hypoglycemia and promote a more physiological glycemic profile than regular human insulin in pregnant women with type 1 (T1D), type 2 (T2D), or gestational (GDM) diabetes. However, there have been concerns regarding potential risk for crossing the placental...
Source: Advances in Therapy - October 26, 2015 Category: Drugs & Pharmacology Source Type: research
Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus
Patients with type 2 diabetes mellitus require insulin as disease progresses to attain or maintain glycaemic targets. Basal insulin is commonly prescribed initially, alone or with one or more rapid-acting prandial insulin doses, to limit mealtime glucose excursions (a basal–bolus regimen). Both patients and physicians must balance the advantages of improved glycaemic control with the risk of hypoglycaemia and increasing regimen complexity. The rapid-acting insulin analogues (insulin aspart, insulin lispro and insulin glulisine) all have similar pharmacokinetic and pharmacodynamic characteristics and clinical efficacy...
Source: Therapeutic Advances in Chronic Disease - October 13, 2015 Category: Internal Medicine Authors: Atkin, S., Javed, Z., Fulcher, G. Tags: Reviews Source Type: research
Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL
Abstract
Insulin lispro 200 U/mL (IL200) is a new strength formulation of insulin lispro (Humalog®, IL100), developed as an option for diabetic patients on higher daily mealtime insulin doses. This phase 1, open‐label, 2‐sequence, 4‐period crossover, randomized, 8‐hour euglycemic clamp study aimed to demonstrate the bioequivalence of IL200 and IL100 after subcutaneous administration of 20 U (U) to healthy subjects (n = 38). Pharmacokinetic (PK) and pharmacodynamic (PD) responses were similar in both formulations. All 90%CIs for the ratios of area under the concentration‐versus‐time curve from time zero t...
Source: Clinical Pharmacology in Drug Development - October 5, 2015 Category: Drugs & Pharmacology Authors: Amparo de la Peña, Mary Seger, Danny Soon, Adam J. Scott, Shobha R. Reddy, Michael A. Dobbins, Patricia Brown‐Augsburger, Helle Linnebjerg Tags: Original Article Source Type: research
Safety of insulin analogs during pregnancy: a meta-analysis
Conclusions
Aspart, glargine, and detemir are safe treatment options for diabetes during pregnancy; these insulin analogs did not increase complications for the mothers or fetuses in our study. However, lispro was related to higher birth weight and increased rate of LGA in neonates. More high-quality randomized controlled trials are needed to clarify the best treatment options for diabetes during pregnancy. (Source: Archives of Gynecology and Obstetrics)
Source: Archives of Gynecology and Obstetrics - September 4, 2015 Category: OBGYN Source Type: research
Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Publication date: Available online 11 August 2015 Source:The Lancet Diabetes & Endocrinology Author(s): Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, John J V McMurray, June Ye Background Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety of albiglutide as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for diabetes. Methods We did a meta-analysis of eight phase 3 trials and one phase 2b trial in which pat...
Source: The Lancet Diabetes and Endocrinology - August 12, 2015 Category: Endocrinology Source Type: research
Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes
Conclusions
Twenty-four-week treatment with exenatide, insulin and pioglitazone improved glucose control in patients with newly diagnosed type 2 diabetes, but had no impact on bone turnover markers or BMD. (Source: Acta Diabetologica)
Source: Acta Diabetologica - August 7, 2015 Category: Endocrinology Source Type: research
Bioequivalence and comparative pharmacodynamics of insulin lispro 200 units/ml relative to insulin lispro (Humalog®) 100 units/ml
This article is protected by copyright. All rights reserved (Source: Clinical Pharmacology in Drug Development)
Source: Clinical Pharmacology in Drug Development - August 6, 2015 Category: Drugs & Pharmacology Authors: Amparo de la Peña, Mary Seger, Danny Soon, Adam J. Scott, Shobha R. Reddy, Michael A. Dobbins, Patricia Brown‐Augsburger, Helle Linnebjerg Tags: Original Article Source Type: research
Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects
Conclusions:
Injection depths in the 5-8 mm range did not affect the PK or GD of insulin lispro in normal weight or obese subjects. (Source: Journal of Diabetes Science and Technology)
Source: Journal of Diabetes Science and Technology - June 30, 2015 Category: Endocrinology Authors: de la Pena, A., Yeo, K. P., Linnebjerg, H., Catton, E., Reddy, S., Brown-Augsburger, P., Morrow, L., Ignaut, D. A. Tags: Original Articles Source Type: research
